Bionano Genomics Completes Its 2021 Fiscal Results

Bionano Genomics, a company specializing in optical genome mapping, today announced that it had provided not full financial results for the Q4 and fiscal year of 2021 that was ended at the end of 2021. For the year ended 2021, Bionano achieved or exceeded all of the company’s goals. Erik Holmlin, the company’s CEO, noted that the company’s BioDiscovery program is doing great, and the results from its first clinical trial made amazing results. For the fourth quarter of 2021, Bionano Genomics is expected to report revenue of $5.8 to $6.2 million, a 25% to 33% increase compared to the third quarter of 2021. For the full year 2021, the company said it expected revenue of $17.8 to $17.9 million, a 110% increase compared to 2020.

Bionano Genomics

For the fourth quarter and the full year 2021, Bionano’s revenue growth is expected to be significantly higher than those recorded in 2020. Chris Stewart, the company’s CFO, said that the company’s robust growth momentum is building momentum for 2022. The company noted that it had not yet completed its financial statements for the quarter and fiscal. As a result, the revenue ranges presented in this press release for the fourth quarter and the year ended December 31, 2021, are preliminary and subject to change.

Anthony Gonzales

Biotech, Tech, and Crypto reporter Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.

Anthony Gonzales has 1700 posts and counting. See all posts by Anthony Gonzales